Market expansion in med derm cross over: Almirall’s Seysara (sarecycline) won NMPA approval for moderate to severe acne (≥9 years), with China commercial launch targeted for 2026 – relevant to ...
As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results